Biotech News
Medicenna Reports More than Doubling of Median Overall Survival in Glioblastoma Patients With Unresectable Recurrent IDH-WT Tumors Following One Treatment with Bizaxofusp Versus a Matched External Control at SNO 2026
Median overall survival (mOS) was 13.7 months with a single high-dose treatment with bizaxofusp vs. 6.2 months for an eligibility-matched and propensity score-balanced external control arm (ECA) in a Phase 3 relevant unresectable IDH-wildtype recurrent glioblastoma (rGBM) patients (N = 19, HR
